Canada markets closed

Lucid Diagnostics Inc. (LUCD)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.9050+0.0150 (+1.69%)
At close: 04:00PM EDT
0.9183 +0.01 (+1.47%)
After hours: 07:54PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close0.8900
Open0.8900
Bid0.8921 x 100
Ask0.9321 x 500
Day's Range0.8800 - 0.9100
52 Week Range0.6300 - 1.8500
Volume85,110
Avg. Volume223,685
Market Cap47.164M
Beta (5Y Monthly)1.49
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • PR Newswire

    PAVmed Provides Business Update and First Quarter 2024 Financial Results

    PAVmed Inc. (NASDAQ: PAVM, PAVMZ) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today provided a business update for the Company and its subsidiaries, Lucid Diagnostics Inc. (NASDAQ: LUCD) ("Lucid") and Veris Health Inc. ("Veris"), and presented financial results for the Company for the three months ended March 31, 2024.

  • PR Newswire

    Lucid Diagnostics Provides Business Update and First Quarter 2024 Financial Results

    Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ( "PAVmed"), today provided a business update for the Company and presented financial results for the three months ended March 31, 2024.

  • PR Newswire

    Legacy Sponge-on-a-String Esophageal Cell Collection Device Subject of Class II FDA Recall

    Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ("PAVmed"), announced that the legacy EsophaCap sponge-on-a-string (SOS) esophageal cell collection device, which it briefly supplied to third-party institutions for their own research studies, has been subjected to a Class II FDA recall due to two serious device failures reported in a recent publica